Therapy Areas: Respiratory
Nanjing Leads Biolabs receives Chinese approval for pivotal Phase III trial of PD-L1/4-1BB bispecific antibody
19 May 2026 - Clinical-stage biotechnology company Nanjing Leads Biolabs Co Ltd (HK:9887) announced on Monday that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received...
CelLBxHealth partners with AdventHealth on cancer monitoring studies
18 May 2026 - CTC intelligence company CelLBxHealth plc (AIM: CLBX) announced on Monday that it has entered a collaboration with AdventHealth, a US-based faith-based health system, to use its Parsorti...
GSK's Arexvy gains expanded approval in Japan for at-risk adults aged 18-49
18 May 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) disclosed on Monday that Japan's Ministry of Health, Labour and Welfare has expanded approval for its RSV vaccine, Arexvy, t...
SN BioScience reports first patient dosed in global Phase 1b/2 clinical trial of SNB-101
15 May 2026 - SN BioScience Inc, a clinical-stage biotechnology company based in South Korea, announced on Thursday that it has started the first patient dosing in its global Phase 1b/2 clinical trial...
SOPHiA GENETICS and Synnovis partner to expand NHS liquid biopsy testing
...
Ranok Therapeutics reports positive Phase 1a clinical results for KRAS G12D inhibitor RNK08954
12 May 2026 - Ranok Therapeutics, a US-based clinical-stage biotechnology company developing innovative therapies, announced on Monday the publication of preliminary clinical results from its Phase 1a...